This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999 Nov;14(6):911-3.

doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h.

Levodopa in the treatment of Parkinson's disease: a consensus meeting

Y Agid¹, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, S Factor, S Fahn, O Gershanik, C Goetz, W Koller, M Kurth, A Lang, A Lees, P Lewitt, D Marsden, E Melamed, P P Michel, Y Mizuno, J Obeso, W Oertel, W Olanow, W Poewe, P Pollak, E Tolosa, et al.

Affiliations

PMID: 10584663
DOI: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h

Review

Levodopa in the treatment of Parkinson's disease: a consensus meeting

Y Agid et al. Mov Disord. 1999 Nov.

. 1999 Nov;14(6):911-3.

doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h.

Authors

Y Agid¹, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, S Factor, S Fahn, O Gershanik, C Goetz, W Koller, M Kurth, A Lang, A Lees, P Lewitt, D Marsden, E Melamed, P P Michel, Y Mizuno, J Obeso, W Oertel, W Olanow, W Poewe, P Pollak, E Tolosa, et al.

Affiliation

¹ INSERM U 289 & Fédération de Neurologie, Hôpital de la Salpêtrière-47, Paris, France.

PMID: 10584663
DOI: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h

No abstract available

PubMed Disclaimer

Similar articles

Is there addiction to levodopa in patients with Parkinson's disease?
Merims D, Galili-Mosberg R, Melamed E. Merims D, et al. Mov Disord. 2000 Sep;15(5):1014-6. doi: 10.1002/1531-8257(200009)15:5<1014::aid-mds1041>3.0.co;2-o. Mov Disord. 2000. PMID: 11009217 No abstract available.
Treatment of Parkinson's disease should begin with a dopamine agonist.
Montastruc JL. Montastruc JL. Mov Disord. 2000 Mar;15(2):361-2. doi: 10.1002/1531-8257(200003)15:2<361::aid-mds1034>3.0.co;2-j. Mov Disord. 2000. PMID: 10752600 No abstract available.
Response to L-dopa in PD: the long and the short of it.
Nutt JG. Nutt JG. Neurology. 2000 May 23;54(10):1884-5. doi: 10.1212/wnl.54.10.1884. Neurology. 2000. PMID: 10822422 Clinical Trial. No abstract available.
Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
Olanow CW, Stocchi F. Olanow CW, et al. Eur J Neurol. 2000 May;7 Suppl 1:3-8. Eur J Neurol. 2000. PMID: 11054152 Review. No abstract available.
[Pharmacotherapy of Parkinson's disease].
Ceballos-Baumann A. Ceballos-Baumann A. MMW Fortschr Med. 2013 May 2;155(8):49-51. doi: 10.1007/s15006-013-0640-7. MMW Fortschr Med. 2013. PMID: 24437138 Review. German. No abstract available.

See all similar articles

Cited by

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Brooks DJ, et al. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. doi: 10.1136/jnnp.74.8.1071. J Neurol Neurosurg Psychiatry. 2003. PMID: 12876237 Free PMC article. Clinical Trial.
Cabergoline : a review of its use in the treatment of Parkinson's disease.
Curran MP, Perry CM. Curran MP, et al. Drugs. 2004;64(18):2125-41. doi: 10.2165/00003495-200464180-00015. Drugs. 2004. PMID: 15341508 Review.
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson's Disease.
Soileau MJ, Pagan FL, Fasano A, Rodriguez-Cruz R, Yan CH, Gupta NR, Teigland CL, Pulungan Z, Schinkel JK, Kandukuri PL, Ladhani OA, Siddiqui MS. Soileau MJ, et al. Neurol Ther. 2023 Apr;12(2):459-478. doi: 10.1007/s40120-022-00433-w. Epub 2023 Jan 18. Neurol Ther. 2023. PMID: 36652111 Free PMC article.
Current status of symptomatic medical therapy in Parkinson's disease.
Factor SA. Factor SA. Neurotherapeutics. 2008 Apr;5(2):164-80. doi: 10.1016/j.nurt.2007.12.001. Neurotherapeutics. 2008. PMID: 18394561 Free PMC article. Review.
Emerging therapies in the pharmacological treatment of Parkinson's disease.
Korczyn AD, Nussbaum M. Korczyn AD, et al. Drugs. 2002;62(5):775-86. doi: 10.2165/00003495-200262050-00005. Drugs. 2002. PMID: 11929331 Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information